WO2009065982A1 - Péptidos con capacidad para unirse a escurfina y aplicaciones - Google Patents
Péptidos con capacidad para unirse a escurfina y aplicaciones Download PDFInfo
- Publication number
- WO2009065982A1 WO2009065982A1 PCT/ES2008/000716 ES2008000716W WO2009065982A1 WO 2009065982 A1 WO2009065982 A1 WO 2009065982A1 ES 2008000716 W ES2008000716 W ES 2008000716W WO 2009065982 A1 WO2009065982 A1 WO 2009065982A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- seq
- phe
- fusion protein
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 312
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 93
- 102100027581 Forkhead box protein P3 Human genes 0.000 title abstract description 14
- 101710088098 Forkhead box protein P3 Proteins 0.000 title abstract description 13
- 150000001413 amino acids Chemical class 0.000 claims abstract description 39
- 208000015181 infectious disease Diseases 0.000 claims abstract description 28
- 230000004071 biological effect Effects 0.000 claims abstract description 27
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000012634 fragment Substances 0.000 claims abstract description 11
- 230000001105 regulatory effect Effects 0.000 claims abstract description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 119
- 210000004027 cell Anatomy 0.000 claims description 107
- 108020001507 fusion proteins Proteins 0.000 claims description 66
- 102000037865 fusion proteins Human genes 0.000 claims description 65
- 230000001506 immunosuppresive effect Effects 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 230000027455 binding Effects 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 20
- 208000035473 Communicable disease Diseases 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 108010078791 Carrier Proteins Proteins 0.000 claims description 6
- 101800001707 Spacer peptide Proteins 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 208000030852 Parasitic disease Diseases 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 206010043276 Teratoma Diseases 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010024612 Lipoma Diseases 0.000 claims description 2
- 206010027145 Melanocytic naevus Diseases 0.000 claims description 2
- 201000004458 Myoma Diseases 0.000 claims description 2
- 208000007256 Nevus Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000000271 mature teratoma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000008798 osteoma Diseases 0.000 claims description 2
- 208000003154 papilloma Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 208000023525 immature teratoma Diseases 0.000 claims 1
- 201000000289 malignant teratoma Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 46
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 7
- 230000002458 infectious effect Effects 0.000 abstract description 7
- 235000001014 amino acid Nutrition 0.000 description 41
- 229940024606 amino acid Drugs 0.000 description 40
- 230000002401 inhibitory effect Effects 0.000 description 30
- 238000003556 assay Methods 0.000 description 29
- 230000004044 response Effects 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108010074328 Interferon-gamma Proteins 0.000 description 23
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 23
- 102100037850 Interferon gamma Human genes 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 239000012636 effector Substances 0.000 description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 16
- -1 hereinafter Proteins 0.000 description 15
- 230000007170 pathology Effects 0.000 description 15
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 210000004988 splenocyte Anatomy 0.000 description 13
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 238000003501 co-culture Methods 0.000 description 8
- 210000003162 effector t lymphocyte Anatomy 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 210000003289 regulatory T cell Anatomy 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 102100021688 Rho guanine nucleotide exchange factor 5 Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 6
- 102000003945 NF-kappa B Human genes 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 5
- 108010075205 OVA-8 Proteins 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 101710132601 Capsid protein Proteins 0.000 description 4
- 101710094648 Coat protein Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 101710125418 Major capsid protein Proteins 0.000 description 4
- 101710141454 Nucleoprotein Proteins 0.000 description 4
- 101710083689 Probable capsid protein Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 4
- 101710102803 Tumor suppressor ARF Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000005784 autoimmunity Effects 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 3
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 230000004001 molecular interaction Effects 0.000 description 3
- 210000004976 peripheral blood cell Anatomy 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- XABCFXXGZPWJQP-BYPYZUCNSA-N (S)-3-aminoadipic acid Chemical compound OC(=O)C[C@@H](N)CCC(O)=O XABCFXXGZPWJQP-BYPYZUCNSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N 2,6-diaminopimelic acid Chemical compound OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-REOHCLBHSA-N 3-amino-L-alanine Chemical compound [NH3+]C[C@H](N)C([O-])=O PECYZEOJVXMISF-REOHCLBHSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 2
- 101150019028 Antp gene Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000701027 Human herpesvirus 6 Species 0.000 description 2
- OGNSCSPNOLGXSM-VKHMYHEASA-N L-2,4-diaminobutyric acid Chemical compound NCC[C@H](N)C(O)=O OGNSCSPNOLGXSM-VKHMYHEASA-N 0.000 description 2
- RDFMDVXONNIGBC-LURJTMIESA-N L-2-aminoheptanoic acid Chemical compound CCCCC[C@H](N)C(O)=O RDFMDVXONNIGBC-LURJTMIESA-N 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- OLNLSTNFRUFTLM-BYPYZUCNSA-N N-ethyl-L-asparagine Chemical compound CCN[C@H](C(O)=O)CC(N)=O OLNLSTNFRUFTLM-BYPYZUCNSA-N 0.000 description 2
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
- 208000008636 Neoplastic Processes Diseases 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- 244000191761 Sida cordifolia Species 0.000 description 2
- 101710192266 Tegument protein VP22 Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000013564 activation of immune response Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 230000007416 antiviral immune response Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002434 immunopotentiative effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical group NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 description 1
- JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 101710146995 Acyl carrier protein Proteins 0.000 description 1
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- UBPMOJLRVMGTOQ-GARJFASQSA-N Asp-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)O)N)C(=O)O UBPMOJLRVMGTOQ-GARJFASQSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000006433 Chemokine CCL22 Human genes 0.000 description 1
- 108010083701 Chemokine CCL22 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000070918 Cima Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 108700006830 Drosophila Antp Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010056663 Gastric infection Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101150004541 HOXC8 gene Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- PROLDOGUBQJNPG-RWMBFGLXSA-N His-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O PROLDOGUBQJNPG-RWMBFGLXSA-N 0.000 description 1
- YJBMLTVVVRJNOK-SRVKXCTJSA-N His-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N YJBMLTVVVRJNOK-SRVKXCTJSA-N 0.000 description 1
- TWROVBNEHJSXDG-IHRRRGAJSA-N His-Leu-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O TWROVBNEHJSXDG-IHRRRGAJSA-N 0.000 description 1
- KRBMQYPTDYSENE-BQBZGAKWSA-N His-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 KRBMQYPTDYSENE-BQBZGAKWSA-N 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 1
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100018264 Mus musculus Hoxb4 gene Proteins 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- OLNLSTNFRUFTLM-UHFFFAOYSA-N N-ethylasparagine Chemical compound CCNC(C(O)=O)CC(N)=O OLNLSTNFRUFTLM-UHFFFAOYSA-N 0.000 description 1
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
- 108010065338 N-ethylglycine Proteins 0.000 description 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 241001195348 Nusa Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241001614207 Pamplona Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229940029303 fibroblast growth factor-1 Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229920000550 glycopolymer Polymers 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 101150003074 hoxa5 gene Proteins 0.000 description 1
- 102000055772 human CD81 Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000002501 natural regulatory T cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004540 process dynamic Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 108010018381 streptavidin-binding peptide Proteins 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Definitions
- the invention relates, in general, to peptides that have the ability to bind to scurphin and its applications.
- the invention relates to peptides that inhibit the biological activity of escurfina by means of its direct binding to said protein, and which thus allow to regulate or block the activity of regulatory T lymphocytes (Treg).
- T lymphocytes Treg
- Such peptides can be used in the treatment of pathologies in which it is convenient or necessary to regulate or block, in a controlled manner, the activity of Treg lymphocytes, such as infectious and neoplastic diseases.
- CD4 + CD25 + cells also known as Treg cells or Treg lymphocytes
- Treg cells also known as Treg cells or Treg lymphocytes
- immunosuppressive Takahashi et al. 1998. Int Immunol 10: 1969-80; Thornton & Shevach. 1998. J Exp Med 188: 287-96. These cells were first identified in mice but then have been widely characterized in humans (Dieckmann et al. 2001. J Exp Med 193: 1303-10; Jonuleit et al. 2001. J Exp Med 193: 1285-94; Levings et al. 2001. J Exp Med 193: 1295-302).
- Currently, the existence of a specific immunosuppressive subpopulation is widely accepted by the scientific community and the way to manipulate its activity for clinical use is sought. The main question is how your activity could be modulated.
- Treg lymphocytes are essential for protection against autoimmune diseases and for the prevention of transplant rejection; therefore, the possibility Boosting its activity has great potential in the treatment of autoimmune diseases and organ transplants.
- Treg lymphocytes may be able to inhibit the activation of immune responses against cancer.
- CD4 + CD25 + (Treg) cells are continually slowing down the activation of effector T lymphocytes to prevent autoimmunity processes, but in turn hampering the correct activation of an antitumor response when necessary.
- Immunotherapy harbors high hopes for the treatment of cancer patients. The numerous clinical protocols performed that have used cytokine-based therapies, effector T-cell infusions or vaccination protocols have shown that, in general, cancer immunotherapy is safe.
- Treg lymphocyte access to the tumor is a process dynamic and that exerts an immunosuppressive effect that facilitates the progression of the disease.
- the presence of Treg in the tumor as well as in the peripheral nodules could explain the low efficacy of immunotherapy protocols.
- the control exerted by Treg lymphocytes can limit the magnitude of T-effector responses and cause the infection control to fail.
- some viruses such as hepatitis B (Xu, D. J Immunol, 2006. 177: 739-747), hepatitis C (Boettler, T., J Virol, 2005.
- Treg lymphocytes can be used to block the antiviral immune response and thus allow the establishment of persistent chronic infection. Therefore, it is believed that modulation of the action of Treg lymphocytes may be essential in the development of immunotherapies against cancer or against infectious diseases.
- Treg lymphocytes There is some controversy regarding the mode of action of Treg lymphocytes, but the role of the cytokine TGF- ⁇ (transforming growth factor ⁇ ) in the process of inhibiting effector T cells (Powrie et al. 1996. J Exp Med 183: 2669-74; Somasundaram et al. 2002. Cancer Res 62: 5267-72).
- TGF- ⁇ transforming growth factor ⁇
- Treg lymphocytes that have been described experimentally go through their elimination, by the use of depleting antibodies or by blocking the cytokines they produce and that may be responsible for their activities (TGF- ⁇ , IL-10), but there is no specific inhibitor of this cellular subpopulation.
- Methods that are based on the depletion of regulatory T cells have the disadvantage that they eliminate cells and carry risks of causing autoimmune diseases.
- there are no specific antibodies to regulatory T cells and those that exist can also eliminate effector T cells.
- the immunosuppressive activity of Treg lymphocytes can be regulated or blocked, transiently or temporarily, by inhibiting the activity of scurfin, an essential transcription factor for said Treg lymphocytes to exert their immunosuppressive effect, by the use of peptides capable of not only binding to scurphin but also capable of inhibiting its biological activity.
- peptides capable of binding to scurphin in particular, those peptides capable of inhibiting their biological activity, are potentially useful for the treatment of pathologies that require a temporary or temporary regulation or inhibition of the immunosuppressive activity of Treg lymphocytes, such as , infectious diseases and neoplastic diseases.
- these peptides provide a tool for the study of the biological role of escurfina and Treg lymphocytes.
- one aspect of this invention relates to peptides that They have the ability to bind to scurphin.
- said peptides also have the ability to inhibit the biological activity of escurfina.
- the invention in another aspect, relates to a fusion protein comprising a peptide provided by this invention and a transporter peptide capable of internalizing a peptide in a cell.
- the invention relates to a pharmaceutical composition comprising at least one peptide or fusion protein provided by this invention.
- the invention relates to the use of said peptides and fusion proteins in the preparation of a medicament for the treatment of a pathology that requires a regulation or transient inhibition of the immunosuppressive activity of Treg lymphocytes, such as a disease. Neoplastic or an infectious disease.
- the invention relates to the use of said peptides and fusion proteins in the treatment of a pathology that requires a temporary regulation or inhibition of the immunosuppressive activity of Treg lymphocytes, such as a neoplastic disease or an infectious disease.
- the invention relates to nucleic acids encoding said peptides or said fusion proteins.
- the invention relates to a gene construct comprising a nucleic acid encoding a peptide or a fusion protein provided by this invention.
- the invention relates to a vector comprising said nucleic acid or said gene construct.
- the invention relates to a host cell, such as a transformed host cell, comprising said nucleic acid, said gene construct or said vector.
- the invention relates to a process for producing a peptide, or a fusion protein, provided by this invention comprising culturing said host cells under conditions that allow the expression of said peptide and, if desired, recovering the peptide. , or the fusion protein, obtained.
- the invention relates to the use of said nucleic acids and gene constructs in the preparation of vectors and cells for the treatment of a pathology that requires a regulation or transient inhibition of the immunosuppressive activity of Treg lymphocytes, such as Neoplastic disease or an infectious disease.
- Figure 1 is a graph showing the results of a surface plasmon resonance analysis (SPR) of the biomolecular interaction that occurs between the P60 peptide (SEQ ID NO: 1) and the scurphin, as described in the Example 1 (section 1.3).
- SPR surface plasmon resonance analysis
- the P60 peptide (SEQ ID NO: 1) gives a positive signal that demonstrates its ability to specifically bind to scurphin.
- the result shown is representative of 3 independent experiments.
- Figure 2 is a graph showing the results of a surface plasmon resonance analysis (SPR) of the biomolecular interaction that occurs between the P60 peptide (SEQ ID NO: 1) and its truncated T (I-13) SEQ ID NO: 2, T (IH) (SEQ ID NO: 3) and T (2-15) (SEQ ID NO: 4), and the scurphin (Example 1, section 1.4).
- SPR surface plasmon resonance analysis
- FIG. 3 is a bar chart showing the suppressive activity of the Karpas 299 human cell line (ACC-31, DSMZ, Germany).
- MLR mixed lymphocyte reaction
- PBMC peripheral blood cells
- TCR T cell receptor
- Figure 4 is a bar chart showing the effect of P60 peptide (SEQ ID NO: 1) on the action of human Treg lymphocytes (purified from peripheral blood of a healthy donor using a Miltenyi Biotech kit, Ref 130 - 091-301) on a mixed lymphocyte response (MLR).
- PBMC derived from two blood donors (1x10 5 cells / well from each donor) were mixed and incubated in the presence or absence of Treg lymphocytes (2x10 4 cells / well) (obtained from one of them) and the P60 peptide (SEQ ID NO: 1) (100 ⁇ M). After 3 days in culture, cell proliferation was measured by a conventional tritiated thymidine incorporation assay.
- Treg lymphocytes are capable of inhibiting MLR and the P60 peptide (SEQ ID NO: 1) is capable of reducing the immunosuppressive effect of human Treg lymphocytes on MLR.
- Figure 5 is a bar chart showing the effect of P60 peptide (SEQ ID NO: 1) on the action of natural human Treg lymphocytes (purified from peripheral blood of a healthy donor) on the response of effector cells against stimulation with anti-CD3 / CD28 antibodies bound to microparticles (Dynabeads® CD3 / CD28, Ref 111-31, Dynal).
- the P60 peptide (SEQ ID NO: 1) is capable of inhibiting the immunosuppressive effect of human Treg lymphocytes on activation with anti-CD3 / CD28.
- Figure 6 is a bar chart showing the effect of the P60 peptide (SEQ ID NO: 1) on the action of natural murine Treg lymphocytes (purified from mouse splenocytes by the use of a Miltenyi Biotech kit, Ref: 130-091-041) on the production of IFN- ⁇ by effector T cells against Stimulation with anti-CD3 antibodies (BD-Biosciences).
- Splenocytes from BALB / c mice were cultured (1x10 5 cells / well) in the presence or absence of anti-CD3 antibodies (0.5 ⁇ g / ml), Treg lymphocytes (2x10 4 cells / well) and P60 peptide (SEQ ID NO : 1) (100 ⁇ M).
- the P60 peptide (SEQ ID NO: 1) is capable of inhibiting the immunosuppressive effect of Treg lymphocytes on the production of IFN- ⁇ (measured by a commercial ELISA) by effector cells in response to stimulation with anti- CD3
- Figure 7 is a bar chart showing the effect of the P60 peptide (SEQ ID NO: 1) on the action of natural murine Treg lymphocytes (purified from mouse splenocytes) on the response of effector cells against stimulation by a mixed lymphocyte response (MLR) (measurement of cell proliferation by a conventional tritiated thymidine incorporation assay).
- the effector lymphocytes isolated from BALB / c mice (1x10 5 cells / well) were co-cultured with purified dendritic cells from C57BL / 6 mice, in the presence or absence of BALB / c Treg lymphocytes (2x10 4 cells / well) and in presence or absence of P60 peptide (SEQ ID NO: 1) (100 ⁇ M).
- the P60 peptide (SEQ ID NO: 1) is capable of inhibiting the immunosuppressive effect of Treg lymphocytes on the proliferation of effector cells.
- Figure 8 is a bar chart showing the effect of the P60 peptide (SEQ ID NO: 1) on the action of natural murine Treg lymphocytes (purified from mouse splenocytes) on the response of effector cells against stimulation by an antigen (measured as production of IFN- ⁇ to the culture supernatant).
- the effector lymphocytes isolated from OTl transgenic mice (1x105 cells / well) were co-cultured with CD dendritic cells of C57BL / 6 mice and the SIINFEKL peptide (SEQ ID NO: 7) (10 ⁇ g / ml), in the presence or absence of BALB / c Treg lymphocytes (2x10 4 cells / well) and in the presence or absence of P60 peptide (SEQ ID NO: 1) (100 ⁇ M).
- the P60 peptide (SEQ ID NO: 1) is capable of inhibiting the immunosuppressive effect of Treg lymphocytes on IFN- ⁇ production by specific effector cells of this peptide antigen.
- Figure 9 is a bar chart showing the effect of peptide P60 (SEQ ID NO: 1) on the inhibition of the activation of the transcription factor NF- ⁇ B by the scurphin.
- 293 cells were transfected with the plasmid pNF-kB-Luc (Clontech, Ref 631904) that expresses luciferase under a promoter inducible by the transcription factor NF-kB, in the presence or absence of the plasmid pcDNA, pcDNA-Foxp3 and the P60 peptide (SEQ ID NO: 1) (100 ⁇ M).
- the presence of escurfina in the cells inhibits the expression of luciferase and the presence of the P60 peptide (SEQ ID NO: 1) restores that expression.
- UR relative units.
- Figure 10 illustrates the effect of administration of the P60 peptide (SEQ ID NO: 1) on potentiating the anti-tumor response of vaccination with the AH1 peptide (SEQ ID NO: 8).
- mice immunized with the AH1 peptide (SEQ ID NO: 8) were treated with saline on days 0, 2, 4, 6, 8 and 10 after immunization, while the remaining 11 were treated with 50 nm / P60 peptide mouse (SEQ ID NO: 1) dissolved in saline and administered intraperitoneally (ip).
- Figure 1OA shows the average tumor growth in different groups of BALB / c mice inoculated subcutaneously with 5x10 5 tumor cells (CT26).
- the different groups represent the average tumor evolution in the absence of treatment (Control group, white triangle), treated only with AHl vaccine antigen (black triangle), treated only with the P60 peptide (SEQ ID NO: 1) (white circle) or treated with the vaccine antigen in combination with the P60 peptide (SEQ ID NO: 1) (black circle).
- Figure 1OB shows the survival curves of the different experimental groups (Kaplan-Meier representation). p ⁇ 0.001 indicates the result of the statistical analysis using the log-rank test.
- the invention relates to a peptide, hereinafter, peptide of the invention, capable of binding to scurfin, selected from: a) a peptide of general formula (I) comprising the amino acid sequence:
- X is absent, or, X is present and is X 14 or X 14 -X 15 , where X 14 and Xi 5 , independently of each other, represent an amino acid; b) a variant of the peptide defined in a); and c) a fragment of the peptide defined in a) or of a variant defined in b); and its pharmaceutically acceptable salts.
- peptide refers to a polymer formed by the binding, in a defined order, of alpha-amino acids by a peptide bond, and includes modifications or derivatives thereof, for example, glycosylation, phosphorylation. , acetylation, amidation, etc.
- amino acids of the peptide of the invention may belong to the L series or the D series, preferably, to the L series.
- the amino acids represented by X) 4 and X 15 can be natural amino acids or modified or rare amino acids.
- amino acids are aliphatic amino acids (glycine, alanine, valine, leucine and isoleucine), hydroxylated amino acids (serine and threonine), sulfur amino acids (cysteine and methionine), dicarboxylic amino acids and their amides (aspartic acid, asparagine, glutamic acid and glutamine), the amino acids that have two basic groups (Usina, arginine and histidine), aromatic amino acids (phenylalanine, tyrosine and tryptophan) and cyclic amino acids (proline).
- aliphatic amino acids glycine, alanine, valine, leucine and isoleucine
- hydroxylated amino acids serine and threonine
- sulfur amino acids cyste and methionine
- dicarboxylic amino acids and their amides aspartic acid, asparagine, glutamic acid and glutamine
- amino acids that have two basic groups Usina, arg
- modified or uncommon amino acids include 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2- aminoheptanoic acid, 2- aminoisobutyric acid, 3-aminoisobutyric acid, 2- aminopimelic acid, 2,4-diaminobutyric acid, desmosin, 2,2'-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, hydroxylysine, alo-hydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, alo-isoleucine, N- methylglycine, N-methylisoleucine, 6-N-methyl-lysine, N-methylvaline, norvaline, norleucine, orinithine, etc.
- the peptide of the invention is characterized by its ability to bind to escurfina, and, advantageously, by its ability to inhibit the biological activity of escurfina.
- the binding capacity of a peptide to the scurphin can be determined by any appropriate method that allows the determination of the binding between two molecules (eg, by an affinity test), said method comprising contacting the scurphin with the peptide to be tested under conditions that allow the binding of said peptide to the escurfina and to evaluate the union between the peptide and the escurfina.
- said affinity assay can be performed using the Surface Plasmon Resonance (SPR) technique (Example 1.3), or similar techniques that use radioactively labeled scurphin, or, alternatively, radioactively labeling the peptide to be tested.
- SPR Surface Plasmon Resonance
- this type of affinity assay comprises contacting the scurfin, eg, immobilized in the wells of a plate, with the peptide whose scurphin binding capacity is desired to be known, and, after incubating for an appropriate period of time, analyze the binding of the peptide to the scurphin. Peptides with low affinity for scurfin are removed by washing while peptides with higher affinity remain attached to the scurphin and can be released by breaking the molecular interactions between both molecules, which can be done, for example, by lowering the pH.
- the peptide of the invention is characterized not only by its ability to bind to scurphin, but also by its ability to inhibit the biological activity of scurphin, and, consequently, indirectly, regulate or block, transiently or temporal, immunosuppressive activity of Treg lymphocytes.
- the ability of a peptide to inhibit the biological activity of the scurphin is due to the direct binding of said peptide to the scurphin.
- a peptide to inhibit the biological activity of escurfina can be analyzed, in vitro, by any appropriate conventional method illustrative of such effect, eg: a) by an assay based on the measurement of cell proliferation in a lymphocyte culture.
- T effectors in the presence of an anti-CD3 antibody, Treg lymphocytes and tritiated thymidine, and in the presence or absence of the peptide to be tested; O well b) by an assay based on the co-culture of splenocytes of transgenic OT-I mice (mice in which the T lymphocytes have a specific T cell receptor for the SIINFEKL peptide (SEQ ID NO: 7) of the ovalbumin) with Treg lymphocytes in the presence of antigen [SIINFEKL peptide (SEQ ID NO: 7)], in the presence or absence of Treg lymphocytes, and in the presence or absence of the peptide to be tested; or alternatively c) by an assay based on a mixed lymphocyte response (MLR) in which effector cells of a mouse (eg, BALB / c) are mixed with dendritic cells obtained from another strain of mouse (eg, C57BL / 6 ) in the presence or absence of Treg lymph
- Example 3 describes in detail different tests aimed at assessing the ability of the peptide to be tested (e.g., a peptide of the invention) to inhibit the biological activity of scurphin in vitro.
- the peptide of the invention is a peptide of general formula (I) comprising the amino acid sequence:
- the peptide of the invention is a peptide of general formula (Ia) [peptide of formula (I) in which X is X 14 -X 15 ] and comprises, or is constituted by, the amino acid sequence:
- X 14 and X 15 independently of each other, represent a natural amino acid (eg, GIy, Ala, Val, Leu, He, Ser, Thr, Cys, Met, Asp, Asn, GIu, GIn, Lys, Arg, His, Phe, Tyr, Trp or Pro) or a modified or rare amino acid (eg, Aad, bAad, bAla, Abu, 4Abu, Acp, Ahe, Aib, bAib, Apm, Dbu, Des, Dpm, Dpr, EtGIy, EtAsn, HyI, aHyl, 3Hyp, 4Hyp, Ide, alie, MeGIy, Melle, MeLys, MeVaI, Nva, NIe or Orn).
- a natural amino acid eg, GIy, Ala, Val, Leu, He, Ser, Thr, Cys, Met, Asp, Asn, GIu, GIn, Lys,
- the peptide of the invention is a peptide comprising, or is constituted by, the amino acid sequence: Arg-Asp-Phe-Gln-Ser-Phe-Arg-Lys-Met-Trp-Pro- Phe-Phe-Ala-Met (SEQ ID NO: 1)
- SEQ ID NO: 1 The peptide constituted by SEQ ID NO: 1 is sometimes identified in this description as a P60 peptide.
- the peptide of the invention is a peptide of general formula (Ib) [peptide of formula (I) in which X is X 14 ] and comprises, or is constituted by, the amino acid sequence:
- X is X 14
- X 14 represents a natural amino acid such as GIy, Ala, Val, Leu, He, Ser, Thr, Cys, Met, Asp, Asn, GIu, GIn, Lys, Arg, His, Phe, Tyr , Trp or Pro, or a modified or rare amino acid (eg, Aad, bAad, bAla, Abu, 4Abu, Acp, Ahe, Aib, bAib, Apm, Dbu, Des, Dpm, Dpr, EtGIy, EtAsn, HyI, aHyl , 3Hyp, 4Hyp, Ide, alie, MeGIy, Melle, MeLys, MeVaI, Nva, NIe or Orn), preferably Ala.
- a natural amino acid such as GIy, Ala, Val, Leu, He, Ser, Thr, Cys, Met, Asp, Asn, GIu, GIn, Ly
- the peptide of the invention is a peptide comprising, or consisting of, the amino acid sequence: Arg-Asp-Phe-Gln-Ser-Phe-Arg-Lys-Met-Trp-Pro-Phe- Phe-Ala (SEQ ID NO: 2)
- the peptide of the invention is a peptide of general formula (Ic) [peptide of formula (I) in which X is absent] and comprises, or is constituted by, the amino acid sequence:
- the peptide of the invention is a peptide consisting of the amino acid sequence:
- the peptide of the invention is a variant of the peptide of general formula (I) defined in section a).
- variant refers to a peptide substantially homologous and functionally equivalent to the peptide of general formula (I) defined in section a).
- a peptide is "substantially homologous" to another peptide when its amino acid sequence has an identity degree of at least 50%, advantageously of at least 60%, preferably of at least , 70, more preferably of at least 80%, still more preferably of at least 90%, and even more preferably of at least 95%.
- the term “functionally equivalent”, as used herein, means that the peptide in question (variant) maintains the ability to bind to scurphin, and, advantageously, to inhibit, in vitro and / or in vivo, biological activity of the scurphin.
- the binding ability of a peptide to the scurphin can be determined by any appropriate conventional method, as previously mentioned, for example, by an affinity test, such as an affinity test based on the Plasmon Resonance technique of Surface (SPR) (Example 1.3).
- SPR Plasmon Resonance technique of Surface
- the ability of a peptide to inhibit the biological activity of the scurphin can be determined by any appropriate conventional method, as previously mentioned, for example, by any of the assays described in Example 3.
- the peptide of the invention is a variant that has one or more insertions, deletions and / or modifications of one or more amino acids of the amino acid sequence shown in section a), and maintains the ability to bind to scurphin.
- said variant comprises one or more conservative amino acid substitutions, relative to the aforementioned amino acid sequence.
- the peptide of the invention is a fragment of the peptide of general formula (I) defined in section a) or of the variant defined in section b).
- fragment refers to a peptide comprising a portion of at least 5 consecutive amino acids, of the peptide of general formula (I) defined in section a), or of the variant defined in section b), that is, a sequence of at least 5 amino acids contiguous within the amino acid sequence of the general formula (I) mentioned in said a), or of the variant defined in b), which maintains the ability to bind to scurphin.
- the peptide of the invention is a fragment of the peptide of general formula (I) defined in a), or of the variant defined in b), which comprises 5 or more (i.e., 6, 7, 8, 9, 10, 11, 12, 13 14 or 15) contiguous amino acids of the amino acid sequence of the general formula (I) mentioned in section a), or of the variant defined in section b), in which they have been one or more amino acids removed either from the amino terminal end, either from the carboxyl terminal end, or both ends, which maintains the ability to bind to scurphin, and, advantageously, the ability to inhibit the biological activity of scurphin.
- the binding capacity of a peptide fragment to the scurphin can be determined by any appropriate conventional method, as previously mentioned, for example, by an affinity test, such as an affinity test based on the SPR technique (Example 1.3).
- an affinity test such as an affinity test based on the SPR technique (Example 1.3).
- the ability of a peptide fragment to inhibit the biological activity of scurphin can be determined by any appropriate conventional method, as previously mentioned, for example, by any of the assays described in Example 3.
- pharmaceutically acceptable salts of the peptide of the invention include the salts commonly used to form metal salts or acid addition salts. The nature of the salt is not critical as long as it is pharmaceutically acceptable.
- Pharmaceutically acceptable salts of the peptide of the invention can be obtained from organic or inorganic acids or bases. Said salts can be obtained by conventional methods well known to those skilled in the art.
- the peptide of the invention is a peptide capable of binding to scurphin and inhibiting its biological activity whose amino acid sequence comprises or is constituted by SEQ ID NO: 1, a variant or fragment thereof, and its pharmaceutically acceptable salts.
- said peptide is capable of binding to scurphin and inhibiting its biological activity, and indirectly, of regulating or temporarily blocking, the immunosuppressive activity of Treg lymphocytes.
- the peptide of the invention may be fused to another peptide thereby constituting a fusion protein. Since the interaction between the peptide of the invention and the scurphin must occur inside the cell (eg, in the cytoplasm and / or in the nucleus), the peptide to which the peptide of the invention is fused is, advantageously, a peptide capable of facilitating the entry of the peptide of the invention into the cell.
- the invention relates to a fusion protein of the invention comprising: (i) a peptide of the invention, and
- a "transport peptide capable of internalizing a peptide in a cell”, sometimes identified in this description as a “transport peptide”, is a peptide capable of crossing the cell membrane and penetrating a cell from the outside, a characteristic that can be conferred to the peptide (eg, peptide of the invention) to which it is fused (fusion protein of the invention) thereby providing an alternative to the transport of peptides of interest (eg, peptides of the invention) into the target cells.
- This mechanism of entry of peptides into the cell is known as "protein transduction or delivery”.
- any transporter peptide capable of internalizing a peptide in a cell can be used for the implementation of the present invention; however, in a particular embodiment, said carrier peptide is a peptide comprising a segment "PTD" (from the English “protein transduction domain").
- proteins comprising said protein transduction domains include the TAT (transacting translational protein) protein of human immunodeficiency virus 1 (HIV-I), the factor of Homeotic transcription (Antp) of Drosophila antennapedia and the VP22 DNA binding protein of simple herpesviruses 1 (HSV-I), although it has also been suggested that this property of internalizing peptides in cells is possessed by other proteins such as influenza virus hemagglutinin , lactoferrin, fibroblast growth factor 1, fibroblast growth factor 2 and Hoxa-5, Hoxb-4 and Hoxc-8 proteins (Ford KG et al., Gene Therapy, 2001; 8: 1-4 ).
- TAT transacting translational protein
- HIV-I human immunodeficiency virus 1
- Adp factor of Homeotic transcription
- HSV-I simple herpesviruses 1
- said carrier peptide is a peptide derived from the HIV-I TAT protein, comprising the sequence responsible for the transduction of peptides, whose basic domain (PTD) comprises residues 49-57 of said HIV TAT protein -I, specifically, the amino acid sequence RKKRRQRRR (SEQ ID NO: 9), or residues 47-57 of said HIV-I TAT protein, such as the peptide whose amino acid sequence is YGRKKRRQRRR (SEQ ID NO: 10) or the peptide whose amino acid sequence is CGISYGRKKRRQRRR (SEQ ID NO: 11).
- said carrier peptide is a peptide derived from the D.
- antennapedia Antp protein which comprises the antennapedia homeodomain (AntpHD) comprising the domain responsible for transduction of peptides (PTD) [residues 43-58 of said Antp protein), which comprises the amino acid sequence RQIKIWFQNRRMKWKK (SEQ ID NO: 12), or a functional fragment thereof.
- said carrier peptide is a peptide derived from HSV-I VP22 protein that comprises a domain responsible for peptide transduction (PTD).
- said carrier peptide is a peptide derived from the ARF tumor suppressor protein (alternative reading frame) comprising the amino acid sequence responsible for the ability of the peptide to penetrate cells, such as the fragment that it comprises residues 26-44 of said ARF protein, namely, the amino acid sequence KFVRSRRPRT ASCALAFVN (SEQ ID NO: 13), or a fragment thereof comprising residues 37-44 of said ARF protein, namely, the amino acid sequence SCALAFVN ( SEQ ID NO: 14).
- the peptide of the invention may be attached to any of the terminal (amino or carboxyl) ends of the transporter peptide capable of internalizing a peptide of the invention in a cell.
- the carboxyl terminal end of the peptide of the invention is attached to the amino terminal end of said transport peptide, while, in another particular embodiment, the amino terminal end of the peptide of the invention is attached to the carboxyl terminal end of said transport peptide.
- the peptide of the invention can be directly or not directly linked to said transport peptide capable of internalizing a peptide in a cell. Therefore, in a particular embodiment, the peptide of the invention [peptide (i)] is directly linked to said carrier peptide [peptide (ii)], while, in another particular embodiment, the peptide of the invention [peptide (i )] is linked to said transporter peptide [peptide (ii)] through a spacer peptide ("linker” or "spacer") between said peptides (i) and (ii).
- the fusion protein of the invention may further contain a spacer peptide located between said peptide of the invention [peptide (i)] and said carrier peptide [peptide (ii)].
- said spacer peptide is a structurally flexible peptide, such as a peptide that gives rise to an unstructured domain.
- any peptide with structural flexibility can be used as a spacer peptide; however, illustrative, non-limiting examples of such spacer peptides include peptides containing amino acid residue repeats, eg, GIy and / or Ser, or any other suitable repetition of amino acid residues.
- the fusion protein of the invention may include an amino acid sequence useful for the isolation or purification of the fusion protein of the invention. Said sequence will be located in a region of the fusion protein of the invention that does not adversely affect the functionality of the peptide of the invention. Virtually any amino acid sequence that can be used to isolate or purify a fusion protein (generically referred to as "tag" or “tag” peptides) may be present in said fusion protein of the invention.
- said amino acid sequence useful for isolating or purifying a fusion protein can be, for example, an arginine tail (Arg-tag), a histidine tail (His-tag), FLAG-tag, Strep -tag, an epitope capable of being recognized by an antibody, such as c-myc-tag, SBP-tag, S-tag, calmodulin binding peptide, cellulose binding domain, chitin binding domain, glutathione S- transferase-tag, maltose binding protein, NusA, TrxA, DsbA, Avi-tag, etc. (Terpe K., Appl. Microbiol. Biotechnol.
- ⁇ -galactosidase VSV-glycoprotein (YTDIEMNRLGK) (SEQ ID NO: 15), or an amino acid sequence such as: Ala His GIy His Arg Pro (SEQ ID NO: 16) (2, 4, and 8 copies), Pro lie His Asp His Asp His Pro His Leu Val He His Ser (SEQ ID NO: 17), etc.
- the peptide of the invention has the ability to bind to scurphin, and, in addition, advantageously, the ability to inhibit the biological activity of scurphin, thereby being able, indirectly, to regulate or transiently block the immunosuppressive activity of Treg lymphocytes. Therefore, an important advantage of the peptide of the invention is that through its use it is possible to regulate or block, temporarily or temporarily, the immunosuppressive activity of Treg lymphocytes.
- the use of the peptides of the invention that is, peptides capable of binding to scurphin and, in particular , with the ability to inhibit the biological activity of escurfina by its direct binding to said protein, it does not eliminate Treg lymphocytes, which allows a finer temporal control over its activity.
- the peptides of the invention due to their small size, can be introduced into cells to block the action of scurphin.
- the use of the peptides of the invention opens a window to a potential development of a new family of potentially useful drugs in the treatment of neoplastic diseases and infectious diseases.
- the inhibition of the biological activity of escurfina allows the peptides of the invention to regulate or block, temporarily or temporarily, the immunosuppressive activity of Treg lymphocytes, with which therapies can be developed for the treatment of neoplastic diseases or diseases Infectious diseases in which, in addition, the action of these Treg lymphocytes is selectively and transiently controlled so as to reduce the risk of inducing autoimmunity as a result of their elimination.
- the peptides of the invention can be used in the treatment of a pathology in which it is convenient or necessary to regulate or temporarily or temporarily inhibit the activity Treg lymphocyte immunosuppressant, as in the case of neoplastic diseases or infectious diseases in which Treg lymphocytes can play an immunosuppressive role preventing the proper activation of an effective immune response.
- Treg lymphocytes are capable of suppressing the beneficial action of anti-tumor T cells in cases of melanoma (Wang, HY, J Immunol, 2005. 174: 2661-2670; Viguier, M., F J Immunol, 2004.
- pancreatic cancer and breast cancer pancreatic cancer and breast cancer (Liyanage, U. K., J Immunol, 2002. 169: 2756-2761) as well as hepatocarcinomas (Ormandy, L. A. Cancer Res,
- Treg lymphocytes In infectious diseases, the control exerted by Treg lymphocytes can limit the magnitude of the T effector responses and cause the infection control to fail. Thus, it has been described that some viruses, eg, hepatitis B virus (Xu, D. J Immunol, 2006. 177: 739-747), hepatitis C virus (Boettler, T., J Virol, 2005 79: 7860-7867; Cabrera, R. Hepatology, 2004. 40: 1062-1071; Rushbrook, J Virol, 2005. 79: 7852-7859; Sugimoto, K. Hepatology, 2003.
- viruses eg, hepatitis B virus (Xu, D. J Immunol, 2006. 177: 739-747), hepatitis C virus (Boettler, T., J Virol, 2005 79: 7860-7867; Cabrera, R. Hepatology, 2004. 40: 1062-1071; Rushbrook, J Virol, 2005
- HIV Human immunodeficiency virus
- Aandahl EM J Virol, 2004. 78: 2454-2459; Kinter, AL J Exp Med, 2004. 200: 331-343; Oswald-Richter, K. PLoS Biol2004. 2: E198 ; Weiss, L. Blood, 2004. 104: 3249-3256
- Treg lymphocytes can be used to block the antiviral immune response and thereby allow the establishment of persistent chronic infection.
- neoplastic diseases includes both tumors (that is, tissue alterations that cause an increase in volume, in particular, lumps due to an increase in the number of cells that compose it, regardless of they are benign or malignant in nature), such as cancer (a disease characterized by an uncontrolled proliferation of abnormal cells capable of invading adjacent tissues and spreading to distant organs).
- infectious diseases refers, in general, to diseases caused by infectious agents, eg, viruses, bacteria, fungi, parasites, etc. In these types of processes, infectious or neoplastic (cancerous), the Treg lymphocytes exert a negative effect, since they are able to inhibit the activation of immune responses against infectious or neoplastic processes that would promote healing.
- viral infections that can be treated with the peptides and fusion proteins of the invention include virtually any infection of viral origin, for example, infections caused by hepatitis B virus, hepatitis C, HIV, papillomavirus human, herpesviruses, for example, human herpesviruses, such as herpes simplex virus type 1 (HSV-I), herpes simplex virus type 2 (HSV-2), varicella zoster virus (VZV), cytomegalovirus (CMV), human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7), Epstein-Barr virus (EBV), Kaposi herpesvirus (HHV-8), etc.,
- Illustrative, non-limiting examples of bacterial infections that can be treated with the peptides and fusion proteins of the invention include, but are not limited to infections caused by Mycobacterium leprae, infections caused by Mycobasterium tuberculosis, infections caused by Yersinia pestis, gastric infection. caused by Helicobacter pylori, etc.
- Illustrative, non-limiting examples of fungal infections that can be treated with the peptides and fusion proteins of the invention include, but are not limited to, infections caused by Candida albicans, infections caused by Trichophyton rubrum, infections caused by Aspergillus sp., etc.
- Illustrative, non-limiting examples of parasitic infections that can be treated with the peptides and fusion proteins of the invention include, but are not limited to, leishmaniasis, eg, visceral leishmaniasis, infections such as malaria caused by Plasmodium parasites, toxoplasmosis, etc.
- any infectious or neoplastic process in which Treg lymphocytes play an immunosuppressive role which could affect the cure of the pathology a subject suffers may be susceptible to being treated with the peptide of the invention.
- the peptides and fusion proteins of the invention of the invention can be used to potentiate antiviral or antitumor vaccines, since their administration after vaccination, and the consequent blocking of Treg lymphocytes by the invention peptides during their administration, would allow Boost the response to vaccine components.
- Treg lymphocytes can play a central role in oral antigen tolerance (Huibregtse, IL Gastroenterology, 2007. 133: 517-528), so that the peptides of the invention could be used in situations where want to break that tolerance to orally administered antigens.
- composition For administration to a subject, the peptide of the invention, or the fusion protein of the invention, will be formulated in an appropriate pharmaceutical composition.
- subject refers to any member of a mammalian species and includes, but is not limited to, domestic animals, primates and humans; The subject is preferably a male or female human being of any age or race.
- the invention relates to a pharmaceutical composition, hereinafter pharmaceutical composition of the invention, which comprises a therapeutically effective amount of a peptide of the invention, or of a fusion protein of the invention, together with, at least one pharmaceutically acceptable excipient.
- Said pharmaceutical composition is useful for administration and / or application in the human or animal body, preferably in the human body.
- the pharmaceutical composition of the invention may contain one or more peptides or fusion proteins of the invention, together with, optionally, one or more, regulatory compounds or inhibitors of the immunosuppressive activity of alternative Treg lymphocytes, other than fusion peptides and proteins. of the invention.
- any compound that inhibits or regulates the immunosuppressive activity of Treg lymphocytes, regardless of their mechanism of action (eg, through the inhibition of scurphin or through other mechanisms), other than The peptides and fusion proteins of the invention may be present, if desired, in the pharmaceutical composition of the invention.
- Illustrative, non-limiting examples of inhibitory or regulatory compounds of the activity of alternative Treg lymphocytes, other than the peptides and fusion proteins of the invention, which may be employed in conjunction with the peptides and fusion proteins of the invention include, but are not limited to, anti-CD25, anti-CTLA4, anti-GITR antibodies, TGF-beta, IL-IO or IL-9 cytokine inhibitors, chemotherapeutic agents such as cyclophosphamide or fludarabine, or CCLl 7 or CCL22 chemokine inhibitors among other.
- peptides of the invention instead of antibodies has numerous advantages, since said peptides are small molecules, have greater diffusion capacity and a shorter half-life.
- the peptides of the invention have a high affinity for escurfin but degrade more rapidly than antibodies, and possible adverse side effects can be controlled by appropriate dosing of the peptides of the invention.
- most of the antibodies against Treg lymphocytes cause the elimination of these cells and, therefore, their effect is more lasting, which increases the risk of inducing autoimmune diseases (Stephens, LA, Proc Nati Acad Sci USA , 2005. 102: 17418-17423).
- fusion proteins of the invention also has numerous advantages since they facilitate the entry of the peptide of the invention into the cell, thereby increasing the inhibitory activity of the scurphin activity of the peptides of the invention since the interaction between the peptide of the invention and the scurphin must be performed inside the cell (eg, in the cytoplasm or, perhaps, in the nucleus).
- the peptides and fusion proteins of the invention can be administered by any means that produces contact of the peptide of the invention with the site of action thereof in The human or animal body.
- the amount of peptide, derivative or pharmaceutically acceptable salt thereof, or fusion protein of the invention, which may be present in the pharmaceutical composition provided by this invention may vary within a wide range.
- the dosage for treating said pathologies with the peptides, fusion proteins and / or pharmaceutical compositions of the invention will depend on numerous factors, including the age, condition of the patient, the severity of the disease or pathology, the route and frequency of administration and the peptide or fusion protein of the invention to be administered.
- compositions containing the peptide or fusion protein of the invention may be presented in any form of administration, for example, solid or liquid, and may be administered by any appropriate route, for example, orally, parenterally, rectally or topically. , for which they will include the pharmaceutically acceptable excipients necessary for the formulation of the desired administration form, for example, ointments (lipogels, hydrogels, etc.), eye drops, spray aerosols, injectable solutions, osmotic pumps, etc.
- ointments lipogels, hydrogels, etc.
- eye drops eye drops
- spray aerosols injectable solutions, osmotic pumps, etc.
- the invention relates to the use of a peptide of the invention, or a fusion protein of the invention, in the preparation of a medicament for the treatment of a pathology in which it is convenient or necessary , regulate or block, temporarily or temporarily, the immunosuppressive activity of Treg lymphocytes, such as infectious diseases (eg, viral, bacterial infections, fungal infections, parasitic infections, etc.) and neoplastic diseases, eg, cancer and tumors .
- infectious diseases eg, viral, bacterial infections, fungal infections, parasitic infections, etc.
- neoplastic diseases eg, cancer and tumors .
- the invention relates to the use of a peptide of the invention, or of a fusion protein of the invention, in the treatment of a pathology in which it is convenient or necessary, to regulate or block, so transient or temporary, the immunosuppressive activity of Treg lymphocytes, such as infectious diseases (eg, viral, bacterial infections, fungal infections, parasitic infections, etc.) and neoplastic diseases, eg, cancer and tumors.
- Treg lymphocytes such as infectious diseases (eg, viral, bacterial infections, fungal infections, parasitic infections, etc.) and neoplastic diseases, eg, cancer and tumors.
- the peptide of the invention can be obtained by conventional synthetic methods, for example, by solid phase chemical synthesis techniques, and purified by conventional methods, for example, by high performance liquid chromatography (HPLC). Additionally, if desired, it can be analyzed by conventional techniques, for example, by sequencing and mass spectrometry, amino acid analysis, nuclear magnetic resonance, etc.
- the peptide of the invention can be obtained by peptide synthesis following conventional procedures (Merrifield RB. J Am Chem Soc 1963; 85: 2149-2154) using the Fmoc variant of Atherton (Atherton, E., Logan, JC and Sheppard, RC 1989.
- the fusion protein of the invention can be obtained by a coupling reaction of the peptide of the invention and the carrier peptide capable of internalizing a peptide of the invention in a cell, which have been well obtained by conventional synthetic methods, such as those mentioned previously (eg, chemical synthesis on solid phase), or by recombinant techniques.
- the peptide of the invention, and the fusion protein of the invention can be obtained by recombinant DNA technology. Therefore, in another aspect, the invention provides a DNA sequence encoding a peptide or a fusion protein of the invention. Said DNA sequence can be easily deduced from the amino acid sequence of the peptide or fusion protein of the invention.
- Said DNA sequence may be contained in a DNA construct. Therefore, in another aspect, the invention provides a DNA construct comprising a DNA sequence encoding a fusion peptide or protein of the invention. Said DNA construct may incorporate, operably linked, a sequence regulating the expression of the DNA sequence encoding the peptide or fusion protein of the invention.
- Control sequences are sequences that they control and regulate the transcription and, where appropriate, the translation of the fusion peptide or protein of the invention, and include promoter, terminator, etc. sequences functional in transformed host cells comprising said DNA sequence or construct. In a particular embodiment, said expression control sequence is functional in bacteria.
- said DNA construct further comprises a marker or gene that encodes a motif or for a phenotype that allows the selection of the host cell transformed with said DNA construct.
- the DNA construct provided by this invention can be obtained by using techniques well known in the art (Sambrook et al., "Molecular Cloning, a Laboratory Manual", 2nd ed., Cold Spring Harbor Laboratory Press, NY , 1989 VoI 1-3).
- the invention relates to a vector, such as an expression vector, comprising said DNA sequence or construct.
- a vector such as an expression vector
- the choice of the vector will depend on the host cell into which it will be subsequently introduced.
- the vector where said DNA sequence is introduced can be a plasmid or a vector that, when introduced into a host cell, is integrated or not into the genome of said cell.
- the obtaining of said vector can be carried out by conventional methods known to those skilled in the art (Sambrok et al., 1989, cited sup ⁇ ).
- the invention relates to a host cell, such as a transformed host cell, comprising a DNA sequence or a DNA construct provided by this invention or a vector as mentioned above.
- Said cell can be a prokaryotic or eukaryotic cell.
- the invention relates to a process for producing a peptide of the invention, or a fusion protein of the invention, comprising growing a host cell comprising the sequence, DNA construct or vector provided by this invention. under conditions that allow the production of said peptide or fusion protein of the invention and, if desired, recover said peptide or fusion protein of the invention.
- the conditions for optimizing the culture of said host cell will depend on the host cell used.
- the procedure for producing the peptide or fusion protein of the invention further includes the isolation and purification of said peptide or fusion protein.
- said DNA sequences and DNA constructs provided by this invention can be used in the elaboration of vectors and cells to treat a pathology in which it is convenient or necessary to regulate or temporarily block, the immunosuppressive activity of the Treg lymphocytes. Therefore, in another aspect, the invention relates to the use of said DNA sequences and DNA constructs in the preparation of vectors and cells for the treatment of a pathology in which it is convenient or necessary to regulate or block, temporarily , the immunosuppressive activity of Treg lymphocytes, for example, viral, bacterial, fungal, parasitic infections, etc., and neoplastic diseases.
- said DNA sequence or construct is contacted with a gene transfer vector, such as a viral or non-viral vector.
- a gene transfer vector such as a viral or non-viral vector.
- Viral vectors suitable for practicing this embodiment of the invention include, but are not limited to, adenoviral vectors, adeno-associated vectors, retroviral vectors, lentiviral vectors, alpha-viral vectors, herpesviral vectors, coronavirus-derived vectors, etc.
- Non-viral type vectors suitable for practicing this embodiment of the invention include, but are not limited to naked DNA, liposomes, polyamines, dendrimers, cationic glycopolymers, liposome-polycation complexes, proteins, receptor-mediated gene transfer systems, etc. .
- the invention relates to a method for the identification of peptides with scurphin binding capacity comprising:
- a phage library comprising a plurality of filamentous phages, the genome of each of said phages containing a nucleotide sequence encoding a different peptide linked to the gene of a phage coat protein, whereby each phage contains a different peptide genetically fused to a phage coat protein;
- a phage library composed of a plurality of filamentous bacteriophages was used ( Ml 3) each containing a different 15 amino acid peptide genetically fused to a phage coat protein, in this case attached to the N-terminal end of the pIII coat protein.
- Ml 3 a phage library composed of a plurality of filamentous bacteriophages
- the phage has a 15 amino acid peptide on its surface, in each of the 5 molecules of the surface protein, while inside it contains the DNA encoding said peptide sequence.
- the peptide coding sequence comes from a degenerate sequence in each of the 15 positions with the 20 natural amino acids, which allows the presentation of 1, IxIO 12 possible sequences of 15 amino acids in different phages. The physical relationship,
- said affinity test consists of an in vitro selection protocol called "biopanning". Briefly, said technique consists in the incubation of a set of phages representing, for practical purposes, all variants of peptides of 15 amino acids (in this case), in a plate covered with scurphin, correctly presented for interaction with the peptides carried For the phages.
- phages After incubation, unbound phages are removed by washing and subsequently specifically bound phages are eluted, by a decrease in pH that breaks the molecular interactions between the scurphin and the peptides presented by the phages.
- the eluted phages are then amplified by infection in a bacterial strain. The process is repeated a total of 3 rounds, so that the content of phages that bind specifically and with high affinity to the escurfina is getting richer.
- the concentration of escurfina used to block the plates is reduced progressively in each round, for example, from 2.5 to 0.02 ⁇ g / mL and, finally, 0.002 ⁇ g / mL.
- the phages selected in each round have an increasing degree of affinity for scurphin.
- phages that have been selected for their affinity for escurfina are sequenced with primers. This allows to obtain the sequences of the peptides presented in the phages.
- confirmation tests of the interaction capacity between said peptides and the scurfin can be performed by means of the Biomolecular Interaction Surface Plasmon Resonance (SPR) technique, as shown in Figure 1. and which shows how the P60 peptide (SEQ ID NO: 1), identified by that technique, binds to the scurphin specifically.
- SPR Biomolecular Interaction Surface Plasmon Resonance
- plasmid pDEST15-FOXP3 a glutathione-S-transferase-linked scurphin expression vector (GST) was used as a fusion protein, kindly provided by Dr. Ignacio Casal (National Oncology Research Center, CNIO, Madrid , Spain).
- GST glutathione-S-transferase-linked scurphin expression vector
- Said plasmid was cloned in Escherichia coli BL21 bacteria competent for the expression and subsequent purification of the protein (scurphin).
- the expression of said protein was made from a culture of 0.5 liters of LB culture medium (Sigma, St Louis).
- the bacterial pellet was smooth in a French (Thermo Electron Corporation) press so that the scurphin remained in the supernatant.
- Scurphin purification was carried out by affinity chromatography using GSTrap affinity columns (Ref 17513001, Amersham, Pharmacia) and the FPLC chromatograph platform (fast protein liquid chromatography) (Akta FPLC, Amersham Biosciences). With the fractions collected, a Western Blot was performed to verify the existence of the protein, using anti-Foxp3 antibodies (ab 10564, Abcam). Once the scurphin was isolated and purified, the binding / elution rounds were initiated with the phage library.
- phage libraries The technology associated with phage libraries has been used to identify peptides capable of binding to escurfina. This technique makes it possible to identify peptides that have a high affinity binding with a specific protein (in this case, escurfina), and then quantify, by means of in vitro tests, the ability of the different peptides to inhibit the biological activity of said protein.
- the sequence of the peptides that bind to the scurphin can be deduced from the corresponding DNA sequence after several "biopanning" cycles (generally 3).
- the phage library used for the realization of this example contains 2 x 10 different clones and has been assigned by the laboratory of George P. Smith (Division of Biological Sciences Tucker Hall, University of Missouri, USA).
- the phages present in said phage library were amplified and purified before proceeding with the selection (biopanning).
- 10 ⁇ l of said phage library were amplified using E. coli K91Kan as a host strain (supplied by George P. Smith, Division of Biological Sciences Tucker Hall, University of Missouri) and subsequently purified by 2 precipitations with polyethylene glycol (PEG) / NaCl and a gradient centrifugation of CsCl.
- PEG polyethylene glycol
- the title of the phage suspension, calculated by Spectrometry was 3.82 x 10 14 virions / ml and the number of infectious particles was 1.3 x 10 13 TU / ml.
- the process of selecting peptides capable of binding to scurfin, potentially useful as inhibitors of their biological activity comprises contacting the scurphin with the peptides presented by the phage library.
- the wells of a 96-well plate were drained with scurfine (adding scurphin in a carbonate buffer to said wells and allowing to incubate for 16 hours at 4 ° C), 10 ⁇ l of the phage library was added at a concentration of 3xlO 4 viruses / ml and allowed to incubate for 1-2 hours at room temperature (20-22 0 C).
- phages were removed by washing with PBS / Tween (phosphate buffered saline / polyoxyalkylene derived from esters of sorbitan fatty acids) so that only the specific scurphin phages remained attached to the plate.
- PBS / Tween phosphate buffered saline / polyoxyalkylene derived from esters of sorbitan fatty acids
- These phages specifically bound to escurfina were eluted by a decrease in pH (elution buffer) that breaks the molecular interactions between the escurfina and the peptides presented by the phages.
- the eluted phages were amplified by infection in a bacterial strain (E.
- colonies of bacteria infected by a single phage were obtained, which presented in the degenerated region of their genome a single sequence encoding a single peptide (the selection of bacterial colonies was carried out in the presence of tetracycline whose resistance is given by a gene of resistance to said antibiotic present in the phage genome, so that, in this way, only colonies infected by phages grow and each colony contains the genome of a single phage to which the sequence of a single peptide presented on its surface). Sequencing of this region makes it possible to know its DNA sequence and, therefore, the sequence of the peptide capable of binding to escurfina, potentially inhibitor of the activity of escurfina.
- a commercial ELISA based on an anti-M13 monoclonal antibody from the phage (HRP / Anti-M13 monoclonal conjugate (Ref 27942101, Amersham Pharmacia Biotech)) was performed, in order to select only the phages with higher affinity for scurfin. Briefly, the ELISA was performed using Maxisorp plates (Nunc, Ref: 442404) upholstered with scurphin. The selected phages were dispensed in the wells of the ELISA plate, and, after successive washing, the plate was revealed with the anti-M13 monoclonal antibody.
- Wells with optical densities greater than their respective negative controls contained the most specific peptides for scurphin. Thus, 25 of the initial 47 phages were selected. The 25 selected peptides were chemically synthesized using Fmoc technology in the inventors' laboratory for use in subsequent tests. After performing several in vitro tests to measure the ability of these peptides to inhibit the immunosuppressive action of Treg lymphocytes, the peptide identified as P60 (SEQ ID NO: 1) was selected because it had the highest inhibitory activity in such assays (Example 2).
- the ability of the P60 peptide (SEQ ID NO: 1) to bind to the scurphin was checked by the surface plasmon resonance technique (SPR) of biomolecular interaction using the BIAcore X Biosensor (BIAcore, AB, Uppsala, Swedden).
- Escurfina produced in E. coli and affinity purified using GSTrap columns (Amersham, Pharmacia), was covalently immobilized on the surface of flow cell 2 (FC2) of a CM5 chip (CM Chip Sensor Ref 116Br- 1000-14 , BIAcore, General Electrics) as described in De Crescenzo et al. (JBC 2001, VoI 276; 29632-29643).
- FCl Flow cell 1
- FCl Flow cell 1
- the solutions of each peptide (10 ⁇ M) were injected three times in a 10 mM Hepes buffer, 150 mM NaCl, pH 7.4 at a flow of 30 ⁇ l / min. Binding curves were processed by subtracting the response in FCl from that obtained in FC2. The equilibrium response was compared between peptide P60 (SEQ ID NO: 1) and an irrelevant control peptide of the same size (length), specifically, the peptide whose amino acid sequence is shown in SEQ ID NO: 6, which corresponds to amino acids 123- 137 of the human CD81 receptor.
- MW (P60) / MW (P) Each response was multiplied by a mass correction factor: MW (P60) / MW (P), where MW (P60) is the molecular weight of the P60 peptide (SEQ ID NO: 1) and MW (P) that of the control peptide .
- MW (P60) is the molecular weight of the P60 peptide (SEQ ID NO: 1) and MW (P) that of the control peptide .
- the P60 peptide (SEQ ID NO: 1) gives a positive signal that demonstrates its ability to specifically bind to the scurphin protein.
- the chemically synthesized truncates were the truncated peptides or forms of P60 identified as:
- T (1-13) (SEQ ID NO: 2) [amino acids 1-13 of P60]
- T (IH) (SEQ ID NO: 3) [amino acids 1-14 of P60]
- T (2-15) ( SEQ ID NO: 4) [amino acids 2-15 of P60].
- in vitro assays were performed using the Karpas 299 human cell line (ACC-31, DSMZ, Germany), derived from a human lymphoma, with regulatory T cell profile [Treg lymphocytes] (Wolke et al hit J Mol
- MLR mixed lymphocyte reaction
- interferon-gamma IFN- ⁇
- a commercial ELISA Ref 555138, Pharmingen, San Diego, CA, United States.
- IFN- ⁇ interferon-gamma
- Ref 555138 Pharmingen, San Diego, CA, United States
- the results of the IFN- ⁇ measurement are shown in Figure 3 and provide information on the suppressive activity of the Karpas 299 cell line.
- the P60 peptide capacity SEQ ID NO: 1 to restore IFN- ⁇ production due to MLR.
- Figure 3 shows that the addition of the P60 peptide (SEQ ID NO: 1) (100 ⁇ M) to the co-culture of the MLR with the Karpas 299 cell line is capable of recovering, in part, the production of IFN- ⁇ which is observed in the absence of Karpas 299 cells.
- the inhibitory capacity of the P60 peptide (SEQ ID NO: 1) on the immunosuppressive activity of human Treg lymphocytes was analyzed by 2 different assays: a) by an assay based on a mixed lymphocyte response (MLR); and b) by an assay based on the measurement of IFN- ⁇ production in a culture of human CD4 effector T lymphocytes cultured with microspheres containing anti-CD3 and anti-CD28 antibodies attached to its surface, in the presence or absence of Treg lymphocytes .
- MLR mixed lymphocyte response
- PBMC peripheral blood cells
- Treg lymphocytes CD4 + CD25 + Treg cells
- This MLR assay was performed by incubating 10 5 PBMC cells from each donor and 2x10 4 Treg lymphocytes, in the presence or absence of the P60 peptide (SEQ ID NO: 1) in order to test their ability to block the inhibitory effect of Treg lymphocytes humans. After 3 days of culture, 0.5 ⁇ Ci / well of tritiated thymidine (Amersham, Pharmacia) was added and, after 16 hours, the plates were harvested using a harvester (Filtermate 96 harvester; Packard Instrument, Meriden, CT ) and to carry out the counting of the radioactivity incorporated into the cellular DNA (as a measure of cell proliferation) by means of a scintillation counter (Topcount; Packard Instrument).
- This assay is based on the measurement of IFN- ⁇ production in a culture of 10 5 human CD4 effector lymphocytes cultured with microspheres containing anti-CD3 and anti-CD28 antibodies glued to their surface (Dynabeads® CD3 / CD28; Ref 111.31, Dynal), in the presence or absence of 2x10 4 human Treg lymphocytes (purified as indicated above).
- This test was performed in the presence or absence of the P60 peptide (SEQ ID NO: 1) to assess its inhibitory effect of Treg lymphocytes. After 48 hours of culture, the presence of IFN- ⁇ in the culture supernatants was measured by a commercial ELISA (Ref 555138, Pharmingen).
- Figure 5 shows that microspheres containing anti-CD3 and anti-CD28 antibodies stimulate the production of IFN- ⁇ by T lymphocytes and that the addition of Treg lymphocytes to the cut is capable of inhibiting said IFN- ⁇ production.
- the addition of the P60 peptide (SEQ ID NO: 1) to these co-cultures is again able to block the inhibitory effect of human Treg lymphocytes, partially restoring IFN- ⁇ production in response to the stimulus.
- the inhibitory capacity of the P60 peptide (SEQ ID NO: 1) on the immunosuppressive activity of murine Treg lymphocytes was analyzed by 3 different assays: a) by an assay based on the activation of splenocytes; b) by a mixed lymphocyte response (MLR) assay; and c) by an assay based on the co-culture of splenocytes of transgenic mice with Treg lymphocytes.
- MLR mixed lymphocyte response
- lymphocyte mixed response (MLR) test Secondly, lymphocyte mixed response assays were performed
- the results obtained show that the P60 peptide (SEQ ID NO: 1) is capable of inhibiting the immunosuppressive effect of Treg lymphocytes on the proliferation of effector cells in response to an MLR (Figure 7).
- the effect of the P60 peptide was measured in an assay based on the co-culture of splenocytes of transgenic OT-I mice (whose T lymphocytes have the specific T cell receptor (TCR) for the SIINFEKL peptide (SEQ ID NO: 7) of the ovalbumin, which were kindly assigned by Dr Melero, CIMA Pamplona) with Treg lymphocytes in the presence of antigen (SEQ ID NO: 7) and in the presence or absence of Treg lymphocytes.
- TCR T cell receptor
- Figure 8 shows the effect of the P60 peptide (SEQ ID NO: 1) on the action of murine natural regulatory T cells (purified from mouse splenocytes) on the response of effector cells against stimulation by an antigen (measured as IFN- ⁇ production to the culture supernatant).
- the effector lymphocytes isolated from transgenic OT-I mice (10 5 cells / well) were co-cultured with dendritic cells from C57BL / 6 mice and the SIINFEKL peptide (SEQ ID NO: 7) (10 ⁇ g / ml), in the presence or absence of 2x10 4 BALB / c regulatory T cells in the presence or absence of P60 peptide (SEQ ID NO: 1) (100 ⁇ M).
- the P60 peptide (SEQ ID NO: 1) is capable of inhibiting the immunosuppressive effect of Treg lymphocytes on the production of IFN- ⁇ (measured by commercial ELISA (Ref: 555138, Pharmingen, San Diego, CA)) by the specific effector cells of this peptide antigen.
- the tumor model used for this trial has been a model based on the CT26 colon cancer line, described in a previous work of the inventors' laboratory (Casares et al, 2001. Eur J Immunol 31: 1780-9; Casares et al ., 2003. J Immunol 171: 5931-9), since the inventors had previously shown that, in that model, Treg lymphocytes have an immunosuppressive effect that favors tumor growth (Casares et al., 2003, cited above).
- mice were immunized with the AH1 peptide (SEQ ID NO: 8) as described in Casares et al., 2001, cited supra, in the presence or absence of the peptide P60 (SEQ ID NO: 1).
- mice were injected with 5 x 10 5 CT26 cells subcutaneously, and tumor evolution was measured.
- Tumor growth curves are shown in Figure 1OA while the survival curves of the different groups are shown in Figure 10B Experimental (Representation of Kaplan-Meier).
- p ⁇ 0.001 indicates the result of the statistical analysis using the log-rank test.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008327792A AU2008327792B2 (en) | 2007-11-19 | 2008-11-14 | Peptides that can bind to scurfin and uses thereof |
US12/743,616 US8524860B2 (en) | 2007-11-19 | 2008-11-14 | Peptides with capacity to bind to scurfin and applications |
JP2010534507A JP5385910B2 (ja) | 2007-11-19 | 2008-11-14 | スクルフィンに結合する能力を有するペプチドおよびその用途 |
BRPI0819311-8A BRPI0819311A2 (pt) | 2007-11-19 | 2008-11-14 | Peptídeos com capacidade para se unir a escurfina e aplicações |
CA2706201A CA2706201A1 (en) | 2007-11-19 | 2008-11-14 | Peptides with capacity to bind to scurfin and applications |
CN2008801217329A CN101903514B (zh) | 2007-11-19 | 2008-11-14 | 能与scurfin结合的肽及其应用 |
EP08852484.8A EP2223998B1 (en) | 2007-11-19 | 2008-11-14 | Peptides that can bind to scurfin and uses thereof |
MX2010005520A MX2010005520A (es) | 2007-11-19 | 2008-11-14 | Peptidos con capacidad para unirse a escurfina y aplicaciones. |
RU2010125199/10A RU2502741C2 (ru) | 2007-11-19 | 2008-11-14 | Пептиды со способностью связываться со скурфином и их применение |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200703052 | 2007-11-19 | ||
ES200703052A ES2328776B1 (es) | 2007-11-19 | 2007-11-19 | Peptidos con capacidad para unirse a escurfina y aplicaciones. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009065982A1 true WO2009065982A1 (es) | 2009-05-28 |
Family
ID=40409793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2008/000716 WO2009065982A1 (es) | 2007-11-19 | 2008-11-14 | Péptidos con capacidad para unirse a escurfina y aplicaciones |
Country Status (11)
Country | Link |
---|---|
US (1) | US8524860B2 (es) |
EP (1) | EP2223998B1 (es) |
JP (1) | JP5385910B2 (es) |
CN (1) | CN101903514B (es) |
AU (1) | AU2008327792B2 (es) |
BR (1) | BRPI0819311A2 (es) |
CA (1) | CA2706201A1 (es) |
ES (1) | ES2328776B1 (es) |
MX (1) | MX2010005520A (es) |
RU (1) | RU2502741C2 (es) |
WO (1) | WO2009065982A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2665543A1 (es) * | 2016-10-26 | 2018-04-26 | Fundación Para La Investigación Médica Aplicada | Péptidos de unión a FOXP3 y usos de los mismos |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
HUE046640T2 (hu) | 2009-06-10 | 2020-03-30 | Nono Inc | TAT-internalizáló peptidhez kapcsolt hatóanyag együttes beadása egy hízósejt degranuláció-inhibitorral |
EP3107552B1 (en) * | 2014-02-21 | 2018-03-28 | Cellectis | Method for in situ inhibition of regulatory t cells |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002090600A2 (en) * | 2001-05-08 | 2002-11-14 | Darwin Molecular Corporation | A method for regulating immune function in primates using the foxp3 protein |
WO2006044864A2 (en) * | 2004-10-19 | 2006-04-27 | Duke University | Vaccine adjuvant |
WO2007084775A2 (en) * | 2006-01-20 | 2007-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698015A (en) * | 1995-05-19 | 1997-12-16 | Nikko Company | Conductor paste for plugging through-holes in ceramic circuit boards and a ceramic circuit board having this conductor paste |
JP2002505077A (ja) * | 1997-12-10 | 2002-02-19 | ワシントン大学 | 抗病原体システムおよびその使用方法 |
JP4351807B2 (ja) * | 1998-08-11 | 2009-10-28 | ダーウィン・ディスカバリー・リミテッド | マウスのscurfyの表現型を引き起こす遺伝子およびそのヒトのオルソログの同定 |
US20020102640A1 (en) * | 2000-02-09 | 2002-08-01 | Hubert Rene S. | 83P5G4: a tissue specific protein highly expressed in prostate cancer |
US20030191073A1 (en) * | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
-
2007
- 2007-11-19 ES ES200703052A patent/ES2328776B1/es not_active Expired - Fee Related
-
2008
- 2008-11-14 JP JP2010534507A patent/JP5385910B2/ja not_active Expired - Fee Related
- 2008-11-14 CA CA2706201A patent/CA2706201A1/en not_active Abandoned
- 2008-11-14 BR BRPI0819311-8A patent/BRPI0819311A2/pt not_active IP Right Cessation
- 2008-11-14 MX MX2010005520A patent/MX2010005520A/es active IP Right Grant
- 2008-11-14 RU RU2010125199/10A patent/RU2502741C2/ru not_active IP Right Cessation
- 2008-11-14 US US12/743,616 patent/US8524860B2/en not_active Expired - Fee Related
- 2008-11-14 WO PCT/ES2008/000716 patent/WO2009065982A1/es active Application Filing
- 2008-11-14 AU AU2008327792A patent/AU2008327792B2/en not_active Ceased
- 2008-11-14 CN CN2008801217329A patent/CN101903514B/zh not_active Expired - Fee Related
- 2008-11-14 EP EP08852484.8A patent/EP2223998B1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002090600A2 (en) * | 2001-05-08 | 2002-11-14 | Darwin Molecular Corporation | A method for regulating immune function in primates using the foxp3 protein |
WO2006044864A2 (en) * | 2004-10-19 | 2006-04-27 | Duke University | Vaccine adjuvant |
WO2007084775A2 (en) * | 2006-01-20 | 2007-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
Non-Patent Citations (53)
Title |
---|
AANDAHL, E. M., J VIROL, vol. 78, 2004, pages 2454 - 2459 |
ATHERTON, E.; LOGAN, J. C.; SHEPPARD, R. C., J. CHEM. SOC. PERKIN TRANS., vol. 1, 1989, pages 538 |
BETELLI ET AL., PROC NATL ACAD SCI U S A., vol. 102, 2005, pages 5138 - 43 |
BOETTLER, T., J VIROL, vol. 79, 2005, pages 7860 - 7867 |
CABRERA, R., HEPATOLOGY, vol. 40, 2004, pages 1062 - 1071 |
CASARES ET AL., EUR J IMMUNOL, vol. 31, 2001, pages 1780 - 9 |
CASARES ET AL., J IMMUNOL, vol. 171, 2003, pages 5931 - 9 |
CASARES N ET AL: "CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 171, no. 11, 1 December 2003 (2003-12-01), pages 5931 - 5939, XP002350092, ISSN: 0022-1767 * |
CHIRINOS-ROJAS C.L. ET AL., IMMUNOLOGY, vol. 6, no. 1, 9 January 1999 (1999-01-09), pages 109 - 113 |
CURIEL, T. J., NAT MED, vol. 10, 2004, pages 942 - 949 |
DE CRESCENZO ET AL., JBC, vol. 276, 2001, pages 29632 - 29643 |
DIECKMANN ET AL., J EXP MED, vol. 193, 2001, pages 1303 - 10 |
FORD K.G. ET AL., GENE THERAPY, vol. 8, 2001, pages 1 - 4 |
GUSAROVA G.A. ET AL., J. CLIN. INVEST., vol. 117, no. 1, January 2007 (2007-01-01), pages 99 - 111 |
HUANG, A. Y. ET AL., PROC NATL ACAD SCI U S A, vol. 93, 1996, pages 9730 - 9735 |
HUIBREGTSE, I. L., GASTROENTEROLOGY, vol. 133, 2007, pages 517 - 528 |
JONULEIT ET AL., J EXP MED, vol. 193, 2001, pages 1285 - 94 |
KINTER, A. L., J EXP MED, vol. 200, 2004, pages 331 - 343 |
KOBAYASHI, N., CLIN CANCER RES, vol. 13, 2007, pages 902 - 911 |
LEVINGS ET AL., J EXP MED, vol. 193, 2001, pages 1295 - 302 |
LIYANAGE, U. K., J IMMUNOL, vol. 169, 2002, pages 2756 - 2761 |
MCCONNELL S.J. ET AL., GENE, vol. 151, no. 1-2, 30 December 1994 (1994-12-30), pages 115 - 118 |
MERRIFIELD RB., J AM CHEM SOC, vol. 85, 1963, pages 2149 - 2154 |
NIESNER U. ET AL., BIOCONJUG. CHEM., vol. 13, no. 4, July 2002 (2002-07-01), pages 729 - 36 |
ONIZUKA ET AL., CANCER RES, vol. 59, 1999, pages 3128 - 33 |
ORMANDY, L. A., CANCER RES, vol. 65, 2005, pages 2457 - 2464 |
OSWALD-RICHTER, K. PLOS BIOL2004., vol. 2, pages E198 |
OSWALD-RICHTER, K., PLOS BIOL, vol. 2, 2004, pages E198 |
POWRIE ET AL., J EXP MED, vol. 183, 1996, pages 2669 - 74 |
ROSENBERG ET AL., NAT MED, vol. 10, 2004, pages 909 - 15 |
RUSHBROOK, J VIROL, vol. 79, 2005, pages 7852 - 7859 |
SAKAGUCHI ET AL., J IMMUNOL, vol. 155, 1995, pages 1151 - 64 |
SCHWARZE S.R. ET AL., SCIENCE, vol. 285, no. 5433, 3 September 1999 (1999-09-03), pages 1569 - 72 |
SHIMIZU ET AL., J IMMUNOL, vol. 163, 1999, pages 5211 - 8 |
SMITH G.P., SCIENCE, vol. 228, no. 4705, 14 June 1985 (1985-06-14), pages 1315 - 1317 |
SOMASUNDARAM ET AL., CANCER RES, vol. 62, 2002, pages 5267 - 72 |
STEITZ ET AL., CANCER RES, vol. 61, 2001, pages 8643 - 6 |
STEPHENS, L. A., PROC NATL ACAD SCI U S A, vol. 102, 2005, pages 17418 - 17423 |
SUGIMOTO, K., HEPATOLOGY, vol. 38, 2003, pages 1437 - 1448 |
SUTMULLER ET AL., J EXP MED, vol. 194, 2001, pages 823 - 32 |
TAKAHASHI ET AL., INT IMMUNOL, vol. 10, 1998, pages 1969 - 80 |
TERPE K., APPL. MICROBIOL. BIOTECHNOL., vol. 60, 2003, pages 523 - 525 |
THORNTON; SHEVACH, J EXP MED, vol. 188, 1998, pages 287 - 96 |
VIGUIER, M., F., J IMMUNOL, vol. 173, 2004, pages 1444 - 1453 |
WANG, H. Y., J IMMUNOL, vol. 174, 2005, pages 2661 - 2670 |
WEISS, L., BLOOD, vol. 104, 2004, pages 3249 - 3256 |
WOLKE ET AL., INT J MOL MED., vol. 17, no. 2, February 2006 (2006-02-01), pages 275 - 8 |
WOO, E. Y., CANCER RES, vol. 61, 2001, pages 4766 - 4772 |
WOO, E. Y., CANCER RES, vol. 61, pages 4766 - 4772 |
XU, D., J IMMUNOL, vol. 177, 2006, pages 739 - 747 |
YAGI ET AL., INT IMMUNOL, vol. 16, 4 October 2004 (2004-10-04), pages 1643 - 56 |
YAGI H ET AL: "Crucial role of FOXP3 in the development and function of human CD25+CD", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 16, no. 11, 4 October 2004 (2004-10-04), pages 1643 - 1656, XP003005850, ISSN: 0953-8178 * |
ZUO TAO ET AL: "FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene.", CELL 29 JUN 2007, vol. 129, no. 7, 29 June 2007 (2007-06-29), pages 1275 - 1286, XP002518867, ISSN: 0092-8674 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2665543A1 (es) * | 2016-10-26 | 2018-04-26 | Fundación Para La Investigación Médica Aplicada | Péptidos de unión a FOXP3 y usos de los mismos |
US10654896B2 (en) | 2016-10-26 | 2020-05-19 | Fundación Para La Investigación Médica Aplicada | FoxP3-binding peptides and uses thereof |
US11560407B2 (en) | 2016-10-26 | 2023-01-24 | Fundación Para La Investigación Médica Aplicada | FOXP3-binding peptides and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101903514B (zh) | 2013-07-17 |
BRPI0819311A2 (pt) | 2015-06-16 |
AU2008327792B2 (en) | 2014-04-24 |
US8524860B2 (en) | 2013-09-03 |
RU2010125199A (ru) | 2011-12-27 |
JP5385910B2 (ja) | 2014-01-08 |
CA2706201A1 (en) | 2009-05-28 |
ES2328776B1 (es) | 2010-07-06 |
ES2328776A1 (es) | 2009-11-17 |
EP2223998A1 (en) | 2010-09-01 |
JP2011504108A (ja) | 2011-02-03 |
AU2008327792A1 (en) | 2009-05-28 |
CN101903514A (zh) | 2010-12-01 |
EP2223998B1 (en) | 2015-05-13 |
RU2502741C2 (ru) | 2013-12-27 |
US20100267623A1 (en) | 2010-10-21 |
MX2010005520A (es) | 2010-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11834519B2 (en) | Compositions and methods for modulating γ-c-cytokine activity | |
ES2352855T3 (es) | Nuevos compuestos peptídicos del tumor de wilms. | |
AU2020201174B2 (en) | Modulating gamma - c -cytokine activity | |
TWI441648B (zh) | Foxp3胜肽疫苗 | |
ES2328776B1 (es) | Peptidos con capacidad para unirse a escurfina y aplicaciones. | |
ES2304315B1 (es) | Peptidos con capacidad para unirse a la interleuquina 10 (il-10). | |
KR20190139245A (ko) | 감마-c-사이토카인 활성의 안정한 조절자 | |
Yang et al. | A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency | |
ES2886944T3 (es) | Péptidos | |
US11384119B2 (en) | Compositions and methods for inhibiting CD279 interactions | |
ES2933112T3 (es) | Péptidos de PAGE5 | |
ES2441252T3 (es) | Epítopos promiscuos de linfocitos T CD4 HER-2/NEU | |
JP7212942B2 (ja) | Foxp3結合ペプチド及びその使用 | |
CN108997481B (zh) | 源自于lmp1的抗原短肽 | |
WO2024077376A1 (en) | Novel tumor-specific antigens for myeloid leukemia and uses thereof | |
ITMI20081119A1 (it) | Frammenti di muc16 ad attivita antigenica e composizioni farmaceutiche che li contengono |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880121732.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08852484 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2706201 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010534507 Country of ref document: JP Ref document number: 12743616 Country of ref document: US Ref document number: MX/A/2010/005520 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1847/KOLNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008327792 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008852484 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010125199 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2008327792 Country of ref document: AU Date of ref document: 20081114 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0819311 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100519 |